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ABSTRACT
Objective: To evaluate the prevalence and risk factors for unrecognized invasive carcinoma 
in a series of patients undergoing surgical excision after an office biopsy of vulvar high-grade 
squamous intraepithelial lesion (VHSIL).
Methods: Two hundred and sixteen consecutive patients treated in a tertiary-level referral 
center for vulvar disease in north-western Italy were recruited. Patients' records were 
reviewed by trained personnel. Factors showing a statistically significant (p<0.05) association 
with detection of stromal invasion at excisional surgery in univariate analysis were further 
examined in a backward stepwise multiple logistic regression model.
Results: The median patient age was 50 years (range, 19–88). More than 25% patients with 
VHSIL at biopsy had associated cervical/vaginal intraepithelial neoplasia, and more than 35% 
had a multifocal lesion. Invasive carcinoma was detected in surgical specimens from 24 patients 
(11%). The depth of stromal invasion varied between 0.1 mm and 3.0 mm with a median of 0.5 
mm. In multivariate analysis, the risk of invasive carcinoma detection was greater for patients in 
the highest tertile of age (p=0.008), for patients with a lesion ≥20 mm in size (p=0.013) and with 
clitoral involvement (p<0.001), and for patients presenting with a nodular lesion (p=0.078).
Conclusion: Our study suggests that patient age, lesion size, clitoral involvement and 
nodular appearance in patients with VHSIL at vulvoscopy-directed biopsy are independently 
associated with the risk of unrecognized invasive carcinoma.
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INTRODUCTION
In the treatment of vulvar high-grade squamous intraepithelial lesion (VHSIL) [1], cold 
knife, radiofrequency or laser excision, and vaporization may result in different degrees of 
disfiguring effects. In consideration of the risk of adverse somatic and psychosexual sequelae 
[2-4], less invasive treatments have been developed. These include photodynamic therapy 
and topical use of immunomodulators [2-6].
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In conservative treatments of VHSIL, it is of utmost importance to exclude the presence 
of foci of stromal invasion, which conveys an increased risk of metastatic spread to lymph 
nodes. If biopsy fails to detect the presence of invasive disease, the therapeutic approach and 
follow-up schedule may be suboptimal and survival rates will dramatically decrease [7]. By 
implication, biopsy should be directed—under vulvoscopic guidance—to the area at highest 
risk of invasion in order to obtain representative specimens for histologic evaluation [8-10]. 
Vulvoscopy aims at detecting macroscopic changes in color, thickness and morphology of 
vulvar skin and mucosa. However, while cervical disease can be graded according to opacity, 
margins, contour, vasculature, and staining reactions of potentially abnormal epithelium, 
there is no grading system that helps differentiate vulvar lesions. This contributes to 
explaining why, in the clinical practice, the prevalence of clinically unrecognized stromal 
invasion in VHSIL varies up to over 20% of patients [8,11-14].
These problems call for a research effort to identify clues on how to decrease the risk that 
vulvoscopy-directed biopsy of VHSIL will fail to detect areas of invasive carcinoma. This involves 
identifying the patient and disease characteristics associated with stromal invasion, on which 
physicians could base their decisions for biopsy and subsequent treatment. Current knowledge 
about these characteristics is poor. Patient age is considered a risk factor, but the supporting 
evidence is circumstantial [15]. Moreover, no clinical risk factor has ever been identified [16].
The current article reports an analytical study of the prevalence and determinants of stromal 
invasion undetected at biopsy in a series of VHSIL patients from Italy.
MATERIALS AND METHODS
1. Setting
The study is part of a larger retrospective investigation of clinical presentation, diagnosis, 
treatment, and post-treatment outcomes of vulvar low-grade squamous intraepithelial lesion 
(VLSIL), VHSIL, differentiated-type vulvar intraepithelial neoplasia (dVIN), and invasive 
vulvar carcinoma at a tertiary-level referral center for vulvar disease in north-western Italy. All 
patients are seen on an outpatient basis. The policy for referral and admittance to the center 
has remained unchanged since its establishment in 1981.
2. Diagnosis and treatment
The examination of the vulva was performed under adequate lightening by naked eyes. 
A magnifying lens or a colposcope was used to better evaluate, if deemed necessary, 
the margins of lesions. Routine application of acetic acid was not used because of the 
previously reported high rate of false-positive results [10]. The clinical aspects of vulvar 
squamous intraepithelial lesion were described using the general principles of dermatology, 
defining location, focality, size, color, surface, thickness, and margination of the lesion 
[17]. Subsequently, in the most of suspicious areas, local anesthesia of the biopsy site was 
performed and a cold knife biopsy was taken. A standard diagram and digital images (when 
available) of the lesion were taken. Once the histological diagnosis of VHSIL was established, 
patients were submitted to excisional treatment. Biopsy and surgical specimens were 
processed according to a standard institutional procedure as previously described [18,19].
Ten gynecologists, 6 pathologists, 3 dermatologists and hundreds of residents attended the 
center during the 35 years after its creation. In order to minimize the variability of clinical 
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approaches, the diagnosis and treatment of all suspected cases of VHSIL and invasive 
carcinoma were only performed by 2 gynecologists (MP, LM), and all biopsy and surgical 
specimens were evaluated by 2 dedicated gynecologic pathologists (BG, SP).
3. Patients
The clinical and pathological records of patients histologically diagnosed with VLSIL, VHSIL, 
and dVIN between 1981 and 2014 were reviewed by trained personnel using a structured set of 
items of information. All available data were coded by the principal investigator. For patients 
with multiple diagnoses of vulvar squamous intraepithelial lesion, the index lesion was 
identified. Data from 302 consecutive patients were evaluated. Patients who were diagnosed 
with VLSIL (n=52) and dVIN (n=21), who refused treatment (n=7), and who received 
imiquimod as primary treatment (n=5) were excluded. There remained 216 eligible women.
4. Data analysis
Patient age was categorized into tertiles in order to detect a trend in the risk of unrecognized 
invasive carcinoma (if any) with the highest possible statistical power. The years of treatment 
were grouped into quartiles because of the unpredictable changes in disease care potentially 
associated with the long time span of the study. Lesion size was categorized in 2 groups only 
(<20 mm and ≥20 mm) in order to minimize the mismeasurement bias.
Differences in proportions were tested for significance with the chi-square tests for 
heterogeneity and trend, and the Fisher exact test. Differences in distributions were tested 
with the nonparametric Mann-Whitney test. Statistical significance was set at p<0.05. 
A p-value >0.05 and <0.10 was considered to indicate a borderline level of significance. 
Explanatory factors showing a statistically significant association with invasive carcinoma 
detection in univariate analysis were further examined in a multiple logistic regression 
model with backward stepwise selection of variables. The level of significance for removal of 
variables was set at p=0.10.
RESULTS
1. Patient characteristics
The yellow curve in Fig. 1 shows the frequency distribution of the 216 eligible patients 
according to 5-year age group. Although the pattern was not clearly bimodal, a peak was 
observed at age 40–44 years followed by a second frequency increase between 60–64 
years and 70–74 years. Table 1 gives a summary overview of other major patient and 
disease characteristics. Noteworthily, more than 25% patients had an associated cervical 
intraepithelial neoplasia (CIN) and/or vaginal intraepithelial neoplasia (VAIN), and more than 
one third of lesions were multifocal.
2. Prevalence of unrecognized invasive carcinoma
Invasive carcinoma unrecognized at biopsy was detected in surgical specimens from 24 
patients (11.1%). The depth of stromal invasion varied between 0.1 mm and 3.0 mm with 
a median of 0.5 mm. In 4 of the 24 patients (16.7%), the depth of stromal invasion was 
>1.0 mm. The blue curve in Fig. 1 shows the frequency distribution of patients according 
to age group. Two peaks were observed at age 40–44 years and 70–74 years. Patients with 
unrecognized invasive carcinoma were older than patients free of invasion (median age, 64 
vs. 48 years; p=0.005).
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Fig. 1. Frequency distribution of the 216 study patients according to 5-year age group and unrecognized invasive 
vulvar carcinoma detection at biopsy.
Table 1. Patient and disease characteristics of study cases of VHSIL
Characteristic No.* %
BMI ≥25 53/131 40.5
HIV positivity 14/216 6.5
Associated lesions
CIN and/or VAIN 56/216 25.9
Lichen sclerosus 16/216 7.4
Squamous hyperplasia 17/216 7.9
Other dermatoses† 11/216 5.1
Presence of symptoms 88/216 40.7
Vulvar thirds involved
Upper third 29/128 22.7
Middle third 25/128 19.5
Lower third 60/128 46.9
Multiple 14/128 10.9




Labia majora 85/214 39.7
Labia minora 97/214 45.3
Vestibule 39/214 18.2












BMI, body mass index; CIN, cervical intraepithelial neoplasia; HIV, human immunodeficiency virus; VAIN, vaginal intraepithelial neoplasia; VHSIL, vulvar high-
grade squamous intraepithelial lesion.
*Patients with missing information on each characteristic were excluded from the denominator; †Including lichen planus.
3. Risk factors for unrecognized invasive carcinoma
Table 2 shows the factors significantly associated with the prevalence of unrecognized 
invasive carcinoma in univariate analysis. The highest prevalence was observed in the 
subgroup of patients with involvement of 2 or 3 vulvar thirds (35.7%). Nonsignificant risk 
factors are listed in a footnote. A risk increase of borderline significance (p=0.072) was 
observed among VHSILs involving labia minora (16.5% vs. 6.8%).
Factors listed in Table 2 were examined further in a multiple logistic regression model, 
and 4 of them were demonstrated to be independently associated with the risk of invasive 
carcinoma detection in surgical specimens. As shown in Table 3, this was significantly 
increased for patients in the highest tertile of age, for patients with a lesion size ≥20 mm, 
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Table 2. Significant univariate risk factors for clinically unrecognized invasive vulvar carcinoma detection in VHSIL (n=216)
Risk factor Patients p
Total No. No. (%) with invasive carcinoma
Patient age (tertiles, yr) 0.008*
19–42 71 3 (4.2)
43–62 74 8 (10.8)
63–88 71 13 (18.3)
Year of treatment (quartiles) 0.029*
1981–1994 51 2 (3.9)
1995–2003 59 5 (8.5)
2004–2008 54 9 (16.7)
2009–2014 52 8 (15.4)
Vulvar thirds involved 0.020
Upper third 29 5 (17.2)
Middle third 25 2 (8.0)
Lower third 60 6 (10.0)
Two or three thirds 14 5 (35.7)
Unknown 88 6 (6.8)
Lesion size (largest diameter, mm) 0.007
<20 61 5 (8.2)
≥20 74 15 (20.3)
Unknown 81 4 (4.9)
Multifocality 0.022
No 136 9 (6.6)
Yes 76 14 (18.4)
Unknown 4 1 (25.0)
Involvement of clitoris 0.002
No 173 13 (7.5)
Yes 41 11 (26.8)
Unknown 2 0 (0.0)
Lesion appearance 0.022
Macule 28 1 (3.6)
Nodule 26 5 (19.2)
Papule 54 7 (13.0)
Plaque 49 10 (20.4)
Ulcer 20 0 (0.0)
Unknown 39 1 (2.6)
Reddish color 0.025
No 128 10 (7.8)
Yes 58 12 (20.7)
Unknown 30 2 (6.7)
The following were not significantly (p<0.05) associated with the prevalence of clinically unrecognized invasive carcinoma detection: BMI (<25, ≥25, unknown); 
comorbidity (no, human immunodeficiency virus positivity, other); associated cervical and/or vaginal intraepithelial neoplasia; associated lichen sclerosus, 
squamous hyperplasia, and other dermatoses; symptoms; involvement of labia majora, of labia minora, of vestibule, of posterior fourchette, and of perineum; 
whitish color; hyperpigmentation; unless otherwise indicated, variables were coded as: no, yes, unknown.
BMI, body mass index; VHSIL, vulvar high-grade squamous intraepithelial lesion.
*Test for trend.
and for patients with clitoral involvement. The risk increase for patients presenting with 
a nodular lesion was of borderline statistical significance. The univariate association of 
multifocality with the dependent variable was not confirmed by multivariate analysis.
DISCUSSION
The finding of an unanticipated stromal invasion in a VHSIL confirms that the disease has 
a potential to progress [20] and that it is necessary to raise awareness about the limitations 
of vulvoscopy-directed biopsy in detecting early invasive carcinoma. Vulvoscopy serves two 
distinct functions: the estimation of severity of the lesion and the selection of biopsy site(s). 
Failure to ascertain the presence of stromal invasion may cause the patient to be undertreated 
and may have a strongly adverse impact on prognosis. In turn, this may lead the clinician to 
lose confidence in conservative treatments of VHSIL. According to previously reported case 
series, the biopsy site may be incorrectly selected in as many as 20% of patients [8,12]. The 
proportion was lower in our data, but it must be considered that our institution is a tertiary-
level referral center for vulvar disease and that all diagnostic and treatment procedures were 
performed by the most experienced ones of us.
The rationale of this study is that an improved knowledge of the patient and disease 
characteristics associated with the presence of undetected foci of invasive carcinoma may 
assist the decision making for biopsy and treatment. First, in our data, the prevalence of 
stromal invasion increased regularly with increasing patient age, although a significant excess 
was demonstrated only when comparing the highest tertile of the variable with the lowest 
one. This observation is compatible with the univariate finding of van de Nieuwenhof et al. 
[21] that the risk of subsequent diagnosis of invasive vulvar carcinoma increases with the age 
at diagnosis of usual type vulvar intraepithelial neoplasia. Our observation also lends support 
to another previous study reporting an increased risk of invasive carcinoma detection among 
aged patients specifically presenting with a raised lesion [15]. It must be noted that our result 
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Table 3. Significant multivariate risk factors for clinically unrecognized invasive vulvar carcinoma detection in VHSIL (n=216)
Risk factor OR 95% CI p



















Year of treatment, vulvar thirds involved, multifocality, and reddish color were removed from the model as nonsignificantly contributing to its likelihood (p>0.10).
CI, confidence interval; OR, odds ratio; VHSIL, vulvar high-grade squamous intraepithelial lesion.
was adjusted for the clinical features of VHSIL, which suggests that patient age predicts 
the presence of stromal invasion independently of these. In any case, we can confirm that 
excisional therapies are indicated for postmenopausal women [22].
The second key observation in this study was that the risk of unrecognized invasive carcinoma 
was greater among large-sized lesions. To interpret this finding, it should be noted that 
multivariate analysis did not confirm the causal role of multifocality that previous data had 
indirectly suggested [23]. We believe that lesion size is a confounder of the association between 
multifocality and the risk of invasive carcinoma detection. In other words, the univariate risk 
increase that is apparently due to multifocality is probably accounted for by the associated 
enlargement of the lesion, which indicates more rapid cell growth and spread and a greater 
amount of neoplastic epithelium at risk of progressing to invasive carcinoma. This hypothesis is 
in keeping with the evidence for a relationship between lesion size and disease recurrence [24].
The third, and most interesting, finding of this study was that the clitoral involvement conveyed 
a many-fold higher likelihood of clinically unrecognized stromal invasion. The incidence of 
invasive vulvar carcinoma with clitoral involvement has increased at a particularly rapid pace 
in recent decades, probably because the non-keratinized squamous cell epithelium covering 
the clitoris is less protected from human papillomavirus (HPV) infection [25]. In addition, 
the clitoral location of invasive vulvar carcinoma is associated with larger tumor size, deeper 
stromal invasion, and more frequent spread to lymph nodes. These unfavorable features 
have been related to patients' and physicians' delay in diagnosis [26], and this is a plausible 
explanation for our own observation. Patients' concerns regarding clitoral functionality and 
the hesitation to perform biopsies in order to avoid injury to the clitoral region do probably 
suggest a prolonged expectant management of VHSIL, with delayed diagnosis and clinically 
unrecognized disease progression. This attitude toward biopsy needs careful reflection. 
Although it is reasonable to balance the potential incremental benefit of taking a biopsy against 
functional and psychosexual contraindications, a more liberal biopsy of any suspicious areas is 
necessary to ascertain progression to invasive disease [3] and is especially indicated in patients 
undergoing an expectant management [9]. It is important that the peri-clitoral region be 
carefully inspected moving up the clitoral hood, so that the correct site for biopsy or biopsies be 
identified, and that the size of samples be adequate.
The risk of unrecognized invasive carcinoma detection was also found to be greater in 
nodular lesions, albeit at a weaker level of significance. An interesting analogy exists between 
this association and the well-documented clinical and prognostic significance of nodulation 
in pigmented skin lesions, in which this pattern of clinical presentation predicts rapid cell 
growth, local aggression, and vertical spread [27].
Among negative results, it is of note that human immunodeficiency virus (HIV) positivity 
did not predict the presence of invasive carcinoma. HIV-positive patients were more often 
diagnosed with unrecognized stromal invasion but not to a significant extent (2/14 or 14% vs. 
22/202 or 11%, p=0.48, data not shown) and less than expected [28]. This was probably caused 
by their limited number and by the resulting random variability. In general, HIV-positive 
patients in the study area attend dedicated clinics.
There are several methodological issues in this study that need to be considered. First, 
we cannot completely rule out a selection bias in this single-institution case series. The 
prevalence of some patient characteristics differed from previous studies.
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Second, the long time-span of patient accrual involves the risk that unpredictable time 
changes in disease behavior have introduced a bias in the results. Statistical adjustment for 
the year of diagnosis may be insufficient to control for this problem.
Third, the lack of information on patient HPV status is a limitation of the current study. 
Since HPV DNA is detectable in 87% patients with VIN vs. 29% patients with invasive vulvar 
carcinoma [29], it would be of interest to determine its prevalence among those VHSILs in 
which an early and clinically unrecognized stromal invasion has occurred. In the clinical 
practice, however, HPV DNA testing of specimens from VHSIL is not recommended [1]. In 
addition, during the first decade (1981–1990) of the study period, the specimens were fixed in 
Bouin's solution which prevents DNA analysis.
Last, but not less important, we wish to make a point on our treatment protocol. Since 
the risk of stromal invasion in patients with a biopsy diagnosis of VHSIL has always been a 
concern in our clinical practice, we have exceptionally used topical imiquimod (off-label use) 
as first line therapy, i.e., in 5 patients who have been excluded from this series. More often, 
although in selected patients, imiquimod has been used as adjuvant therapy after surgical 
excision. For the same reason, we do not use laser or radiofrequency vaporization of mucosal 
VHSIL in young patients. According to current practice guidelines [2,3], wide local excision 
is the treatment of choice if a patient with a biopsy diagnosis of VHSIL is suspected to have 
an occult cancer. In this study, we have considered the risk of clinically unsuspected stromal 
invasion, and we have identified some independent determinants. More data are needed 
before we can develop an appropriate statistical algorithm designed to predict the patient's 
individual risk. The ultimate objective is to personalize treatment based on the individual 
disease status, in order to avoid both under- and over-treatment.
We can conclude that patient age, lesion size and appearance, and clitoral involvement were 
independently associated with unrecognized invasive carcinoma detection. The clinical 
correlates of VHSIL progression and the accuracy of vulvoscopy in selecting biopsy sites 
warrant further investigations, possibly on a multicenter basis. In the interim, data currently 
available suggest that aged patients, patients with large and nodular lesions, and patients 
with clitoral involvement require special attention, with a timely, correct, and more liberal 
use of vulvar biopsy and the width of excision precisely tailored to the extent of disease.
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